...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: ESPR

Yes there is value in pursuing LDL lowering. Especially in the crowd that cannot tolerate statins. The ongoing CVOT trials for the anti-PCSK9 antibody therapies will further bolster the contribution of LDL to cardiovascular disease, if successful. LDL and HDL are both still regarded as independent contributors to cardiovascular disease.

BearDownAZ

Share
New Message
Please login to post a reply